Nephron commits to $400M syringe purchase from Sharps Technology

Nephron Pharmaceuticals committed to minimum orders of over $400 million over 10 years from Sharps Technology for copolymer prefillable syringe systems, with first-year revenue of about $30 million and delivery starting Q1 2024.

“Nephron commits to minimum orders of over $400 Million over 10 years; $30 Million in revenue the first year”endata.com

• 1 source
• endata.comNephron commits to over $400M in 10-year syringe purchases from Sharps Technology · EndataSep 26, 2023

Summarized from public sources; check the original articles before acting on it.